Case Name | Date Filed | Judge | Drug | Patent No(s). |
---|---|---|---|---|
Torrent Pharms. Ltd. v. Merck Frosst Canada & Co., IPR2014-00559 (PTAB) |
Apr. 1, 2014 |
N/A |
Daliresp® (roflumilast tablets) |
6,448,274 |
Bayer Pharma AG v. Par Pharm., Inc., 14-2065 (D.N.J.) |
Apr. 2, 2014 |
Hon. Jose L. Linares |
Staxyn® (vardenafil hydrochloride tablets) |
8,613,950 |
Noven Pharms., Inc. v. Novartis AG, IPR2014-00549 (PTAB) |
Apr. 2, 2014 |
N/A |
Exelon® (rivastigmine extended-release film) |
6,316,023 |
Noven Pharms., Inc. v. Novartis AG, IPR2014-00550 (PTAB) |
Apr. 2, 2014 |
N/A |
Exelon® (rivastigmine extended-release film) |
6,335,031 |
Purdue Pharma L.P. v. Teva Pharms. USA, Inc., 14-2357 (S.D.N.Y.) |
Apr. 3, 2014 |
Hon. Sidney H. Stein |
OxyContin® (oxycodone hydrochloride extended-release tablets) |
6,488,963 |
Otsuka Pharm. Co., Ltd. v. Hetero USA Inc., 14-0421 (D. Del.) |
Apr. 4, 2014 |
Hon. Richard G. Andrews |
Samsca® (tolvaptan tablets) |
8,501,730 |
Reckitt Benckiser Pharms. Inc. v. Par Pharm., Inc., 14-0422 (D. Del.) |
Apr. 4, 2014 |
Hon. Richard G. Andrews |
Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) |
8,475,832 |
Sanofi v. Alembic Pharms. Ltd., 14-0424 (D. Del.) |
Apr. 4, 2014 |
Hon. Richard G. Andrews |
Multaq® (dronedarone tablets) |
7,323,493 |
Helsinn Healthcare S.A. v. Cipla Ltd., 14-0427 (D. Del.) |
Apr. 7, 2014 |
Hon. Gregory M. Sleet |
Aloxi® (palonosetron hydrochloride intravenous solution) |
8,598,218 |
Mallinckrodt LLC v. Metrics, Inc., 14-2219 (D.N.J.) |
Apr. 7, 2014 |
Hon. Susan D. Wigenton |
Pennsaid® (diclofenac sodium topical solution) |
8,217,078 |
Kowa Co., Ltd. v. Aurobindo Pharma Ltd., 14-2497 (S.D.N.Y.) |
Apr. 9, 2014 |
Hon. Paul A. Crotty |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Kowa Co., Ltd. v. Aurobindo Pharma Ltd., 14-2290 (D.N.J.) |
Apr. 10, 2014 |
Hon. Peter G. Sheridan |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Novartis Pharms. Corp. v. Dr. Reddy's Labs., Ltd., 14-2329 (D.N.J.) |
Apr. 10, 2014 |
Hon. Claire C. Cecchi |
Gleevec® (imatinib mesylate capsules) |
RE43,932 |
The Medicines Co. v. Aurobindo Pharma Ltd., 14-2367 (D.N.J.) |
Apr. 11, 2014 |
Hon. Peter G. Sheridan |
Angiomax® (bivalirudin for injection) |
7,582,727 |
Glenmark Generics Ltd. v. Sanofi-Aventis U.S. LLC, 14-2374 (D.N.J.) |
Apr. 11, 2014 |
Hon. Stanley R. Chesler |
DDAVP® (desmopressin acetate tablets) |
7,022,340 |
Kowa Co., Ltd. v. Mylan, Inc., 14-2647 (S.D.N.Y.) |
Apr. 14, 2014 |
Hon. Paul A. Crotty |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Eli Lilly and Co. v. Apotex Corp., 14-0586 (S.D. Ind.) |
Apr. 16, 2014 |
Hon. Sarah Evans Barker |
Effient® (prasugrel hydrochloride tablets) |
8,404,703 |
Endo Pharms., Inc. v. Depomed, Inc., IPR2014-00651, -00652 (PTAB) |
Apr. 17, 2014 |
N/A |
Gralise® (gabapentin tablets) |
6,723,340 |
Endo Pharms., Inc. v. Depomed, Inc., IPR2014-00653, -00654 (PTAB) |
Apr. 17, 2014 |
N/A |
Gralise® (gabapentin tablets) |
6,340,475 |
Endo Pharms., Inc. v. Depomed, Inc., IPR2014-00655, -00656 (PTAB) |
Apr. 17, 2014 |
N/A |
Gralise® (gabapentin tablets) |
6,635,280 |
Kowa Co., Ltd. v. Mylan, Inc., 14-0504 (W.D. Pa.) |
Apr. 17, 2014 |
Hon. Arthur J. Schwab |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Kowa Co., Ltd. v. Amneal Pharms., LLC, 14-2758 (S.D.N.Y.) |
Apr. 17, 2014 |
Hon. Paul A. Crotty |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Kowa Co., Ltd. v. Orient Pharma Co., Ltd., 14-2759 (S.D.N.Y.) |
Apr. 17, 2014 |
Hon. Paul A. Crotty |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Kowa Co., Ltd. v. Zydus Pharms. (USA) Inc., 14-2760 (S.D.N.Y.) |
Apr. 17, 2014 |
Hon. Paul A. Crotty |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Hospira, Inc. v. Aurobindo Pharma Ltd., 14-0486 (D. Del.) |
Apr 18, 2014 |
Hon. Gregory M. Sleet |
Precedex® (dexmedetomidine hydrochloride injection) |
6,716,867 |
Hospira, Inc. v. Ben Venue Labs., Inc., 14-0487 (D. Del.) |
Apr 18, 2014 |
Hon. Gregory M. Sleet |
Precedex® (dexmedetomidine hydrochloride injection) |
6,716,867 |
Hospira, Inc. v. Actavis US Holding LLC, 14-0488 (D. Del.) |
Apr 18, 2014 |
Hon. Gregory M. Sleet |
Precedex® (dexmedetomidine hydrochloride injection) |
6,716,867 |
Hospira, Inc. v. Akorn, Inc., 14-2811 (N.D. Ill.) |
Apr 18, 2014 |
Hon. Robert M. Dow, Jr. |
Precedex® (dexmedetomidine hydrochloride injection) |
6,716,867 |
Hospira, Inc. v. Intas Pharms. Ltd., 14-0336 (M.D.N.C.) |
Apr 18, 2014 |
Hon. N. C. Tilley, Jr. |
Precedex® (dexmedetomidine hydrochloride injection) |
6,716,867 |
Kowa Co., Ltd. v. Amneal Pharms., LLC, 14-2488 (D.N.J.) |
Apr. 18, 2014 |
Hon. Peter G. Sheridan |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Forest Labs., Inc. v. Amneal Pharms. LLC, 14-0508 (D. Del.) |
Apr. 21, 2014 |
Hon. Leonard P. Stark |
Namenda XR® (memantine hydrochloride extended-release capsules) |
5,061,703 |
Amarin Pharma, Inc. v. Apotex, Inc., 14-2550 (D.N.J.) |
Apr. 21, 2014 |
Hon. Mary L. Cooper |
Vascepa® (icosapent ethyl capsules) |
8,293,728 |
Amarin Pharma, Inc. v. Roxane Labs., Inc., 14-2551 (D.N.J.) |
Apr. 21, 2014 |
Hon. Mary L. Cooper |
Vascepa® (icosapent ethyl capsules) |
8,293,728 |
Kowa Co., Ltd. v. Zydus Pharms. (USA) Inc., 14-2552 (D.N.J.) |
Apr. 22, 2014 |
Hon. Peter J. Sheridan |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Hyperion Therapeutics, Inc. v. Par Pharm., Inc., 14-0384 (E.D. Tex.) |
Apr. 23, 2014 |
Hon. Rodney Gilstrap |
Ravicti® (glycerol phenylbutyrate oral liquid) |
8,404,215 |
AbbVie, Inc. v. Hetero USA Inc., 14-0543 (D. Del.) |
Apr. 24, 2014 |
Hon. Richard G. Andrews |
Norvir® (ritonavir tablets) |
8,470,347 |
Amarin Pharma, Inc. v. Apotex, Inc. 14-2958 (N.D. Ill.) |
Apr. 24, 2014 |
Hon. James F. Holderman |
Vascepa® (icosapent ethyl capsules) |
8,293,728 |
Dow Pharm. Sciences, Inc. v. Actavis, Inc., 14-2661 (D.N.J.) |
Apr. 25, 2014 |
Hon. Stanley R. Chesler |
Acanya® (clindamycin phosphate / benzoyl peroxide gel) |
8,663,699 |
The Medicines Co. v. Exela Pharma Sciences, LLC, 14-0058 (W.D.N.C.) |
Apr. 25, 2014 |
Hon. Richard Voorhees |
Angiomax® (bivalirudin for injection) |
7,582,727 |
Amarin Pharma, Inc. v. Roxane Labs., Inc., 14-0901 (N.D. Ohio) |
Apr. 25, 2014 |
Hon. Christopher A. Boyko |
Vascepa® (icosapent ethyl capsules) |
8,293,728 |
Otsuka Pharm. Co., Ltd. v. Amneal Pharms., LLC, 14-2700 (D.N.J.) |
Apr. 28, 2014 |
Hon. Mary L. Cooper |
Abilify® (aripiprazole oral solution) |
8,642,600 |
Cephalon, Inc. v. Uman Pharma Inc., 14-0568 (D. Del.) |
Apr. 30, 2014 |
Hon. Gregory M. Sleet |
Treanda® (bendamustine hydrochloride powder per vial for infusion) |
8,445,524 |
Celgene Corp. v. Fresenius Kabi USA, LLC, 14-0571 (D. Del.) |
Apr. 30, 2014 |
Hon. Richard G. Andrews |
Istodax® (romidepsin for injection) |
7,608,280 |
Amarin Pharma, Inc. v. Dr. Reddy's Labs., Inc., 14-2760 (D.N.J.) |
Apr. 30, 2014 |
Hon. Mary L. Cooper |
Vascepa® (icosapent ethyl capsules) |
8,293,728 |
Cephalon, Inc. v. Uman Pharma Inc., 14-3114 (S.D.N.Y.) |
May 1, 2014 |
Hon. Thomas P. Griesa |
Treanda® (bendamustine hydrochloride powder per vial for infusion) |
8,445,524 |
Senju Pharm. Co., Ltd. v. Aurobindo Pharma Ltd., 14-0579 (D. Del.) |
May 2, 2014 |
Hon. Sue L. Robinson |
Zymaxid® (gatifloxacin) ophthalmic solution) |
6,333,045 |
Impax Labs., Inc. v. Meda Pharms., Inc., IPR2014-00731 (PTAB) |
May 7, 2014 |
N/A |
Astepro® (azelastine hydrochloride nasal spray) |
8,071,073 |
Kowa Co., Ltd. v. Orient Pharma Co., Ltd., 14-3336 (N.D. Ill.) |
May 7, 2014 |
Hon. Matthew F. Kennelly |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Cephalon, Inc. v. Innopharma, Inc., 14-0590 (D. Del.) |
May 9, 2014 |
Hon. Gregory M. Sleet |
Treanda® (bendamustine hydrochloride powder for IV) |
8,609,863 |
Otsuka Pharm. Co., Ltd. v. Almebic Pharms. Ltd., 14-2982 (D.N.J.) |
May 9, 2014 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
8,017,615 |
Alza Corp. v. Mylan Pharms. Inc., 14-0594 (D. Del.) |
May 12, 2014 |
Hon. Richard G. Andrews |
Concerta® (methylphenidate hydrochloride) |
8,163,798 |
Alza Corp. v. Mylan Pharms. Inc., 14-0085 (N.D.W.V.) |
May 15, 2014 |
Hon. Irene M. Keeley |
Concerta® (methylphenidate hydrochloride) |
8,163,798 |
Celgene Corp. v. Natco Pharma Ltd., 14-3126 (D.N.J.) |
May 15, 2014 |
Hon. Susan D. Wigenton |
Revlimid® (lenalidomide capsules) |
8,530,498 |
Otsuka Pharm. Co., Ltd. v. Zydus Pharms. USA Inc., 14-3168 (D.N.J.) |
May 16, 2014 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
8,017,615 |
Dr. Reddy's Labs., Inc. v. Purdue Pharm. Products L.P., 14-3230 (D.N.J.) |
May 20, 2014 |
Hon. Jose L. Linares |
Intermezzo® (zolpidem tartrate sublingual tablets) |
7,658,945 |
Jazz Pharms., Inc. v. Amneal Pharms., LLC, 14-3235 (D.N.J.) |
May 20, 2014 |
Hon. Esther Salas |
Xyrem® (sodium oxybate oral solution) |
8,589,182 |
Alcon Research, Ltd. v. Watson Labs., Inc., 14-0647 (D. Del.) |
May 20, 2014 |
Hon. Sue L. Robinson |
Travatan Z® (travoprost ophthalmic solution) |
8,268,299 |
Amarin Pharma, Inc. v. Watson Labs., Inc., 14-3259 (D.N.J.) |
May 21, 2014 |
Hon. Mary L. Cooper |
Vascepa® (icosapent ethyl capsules) |
8,293,728 |
Allergan, Inc. v. Actavis PLC, 14-0638 (E.D. Tex.) |
May 22, 2014 |
Hon. Rodney Gilstrap |
Restasis® (cyclosporine ophthalmic emulsion 0.05%) |
8,633,162 |
Otsuka Pharm. Co., Ltd. v. Aurobindo Pharma Ltd., 14-3306 (D.N.J.) |
May 23, 2014 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
8,017,615 |
AstraZeneca AB v. Aurobindo Pharma Ltd., 14-0664 (D. Del.) |
May 23, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) |
7,951,400 |
AstraZeneca AB v. Glenmark Generics Ltd., 14-0665 (D. Del.) |
May 23, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) |
7,951,400 |
AstraZeneca AB v. Watson Labs., Inc., 14-0666 (D. Del.) |
May 23, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) |
7,951,400 |
AstraZeneca AB v. Wockhardt BIO AG, 14-0667 (D. Del.) |
May 23, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) |
RE44,186 |
AstraZeneca AB v. Watson Labs., Inc., 14-3428 (D.N.J.) |
May 24, 2014 |
Hon. Mary L. Cooper |
Onglyza® (saxagliptin hydrochloride tablets) |
7,951,400 |
Cephalon, Inc. v. Breckenridge Pharm., Inc., 14-0671 (D. Del.) |
May 27, 2014 |
Hon. Gregory M. Sleet |
Treanda® (bendamustine hydrochloride powder for IV) |
8,445,524 |
Torrent Pharms. Ltd. v. Novartis AG, IPR2014-00784 (PTAB) |
May 27, 2014 |
N/A |
Gilenya® (fingolimod capsules) |
8,324,283 |
Pack Pharms. LLC v. Alza Corp., IPR2014-00868 (PTAB) |
May 30, 2014 |
N/A |
Glucotrol® XL (glipizide extended release tablets) |
RE44,459 |
Forest Labs., Inc. v. Ranbaxy, Inc., 14-0686 (D. Del.) |
May 30, 2014 |
Hon. Leonard P. Start |
Namenda XR® (memantine hydrochloride extended-release capsules) |
8,168,209 |
Otsuka Pharm. Co., Ltd. v. Wockhardt Bio AG, 14-3445 (D.N.J.) |
May 30, 2014 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
8,642,760 |
Apotex Corp. v. ViiV Healthcare UK Ltd., IPR2014-00876 (PTAB) |
June 2, 2014 |
N/A |
Epzicom® (abacavir sulfate / lamivudine tablets) Trizivir® (abacavir sulfate / lamivudine / zidovudine tablets) |
6,417,191 |
AstraZeneca AB v. Sun Pharma Global FZE, 14-0694 (D. Del.) |
June 2, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) Kombiglyze XR™ (saxagliptin hydrochloride / metformin hydrochloride extended-release tablets) |
RE44,186 7,951 |
AstraZeneca AB v. Teva Pharm. USA, Inc., 14-0695 (D. Del.) |
June 2, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) |
7,951,400 |
AstraZeneca AB v. Mylan Pharms., Inc., 14-0696 (D. Del.) |
June 2, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) Kombiglyze XR™ (saxagliptin hydrochloride / metformin hydrochloride extended-release tablets) |
RE44,186 |
AstraZeneca AB v. Amneal Pharms. LLC, 14-0697 (D. Del.) |
June 2, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) Kombiglyze XR™ (saxagliptin hydrochloride / metformin hydrochloride extended-release tablets) |
RE44,186 |
AstraZeneca AB v. Apotex Corp., 14-0698 (D. Del.) |
June 2, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) |
7,951,400 |
Gilead Sciences, Inc. v. Mylan Inc., 14-3928 (S.D.N.Y.) |
June 2, 2014 |
Hon. Richard J. Sullivan |
Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) |
6,642,245 |
AstraZeneca Pharms. LP v. Sandoz Inc., 14-3547 (D.N.J.) |
June 3, 2014 |
Hon. Renee Marie Bumb |
Faslodex® (fulvestrant injection) |
6,774,122 |
AstraZeneca AB v. Sun Pharma Global FZE, 14-3552 (D.N.J.) |
June 3, 2014 |
Hon. Mary L. Cooper |
Onglyza® (saxagliptin hydrochloride tablets) Kombiglyze XR™ (saxagliptin hydrochloride / metformin hydrochloride extended-release tablets) |
RE44,186 |
AstraZeneca AB v. Mylan Pharms., Inc., 14-0094 (N.D.W.V.) |
June 3, 2014 |
Hon. Irene M. Keeley |
Onglyza® (saxagliptin hydrochloride tablets) Kombiglyze XR™ (saxagliptin hydrochloride / metformin hydrochloride extended-release tablets) |
RE44,186 |
Mylan Pharms. Inc. v. Gilead Sciences, Inc., IPR2014-00885 (PTAB) |
June 4, 2014 |
N/A |
Stribild® (cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil fumarate tablets) |
5,922,695 |
Mylan Pharms. Inc. v. Gilead Sciences, Inc., IPR2014-00886 (PTAB) |
June 4, 2014 |
N/A |
Stribild® (cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil fumarate tablets) |
5,935,946 |
Mylan Pharms. Inc. v. Gilead Sciences, Inc., IPR2014-00887 (PTAB) |
June 4, 2014 |
N/A |
Stribild® (cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil fumarate tablets) |
5,977,089 |
Mylan Pharms. Inc. v. Gilead Sciences, Inc., IPR2014-00888 (PTAB) |
June 4, 2014 |
N/A |
Stribild® (cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil fumarate tablets) |
6,043,230 |
Helsinn Healthcare S.A. v. Mylan, Inc., 14-0709 (D. Del.) |
June 4, 2014 |
Hon. Gregory M. Sleet |
Aloxi® (palonosetron hydrochloride intravenous solution) |
7,947,724 |
Amarin Pharma, Inc. v. Teva Pharms. USA, Inc., 14-3558 (D.N.J.) |
June 4, 2014 |
Hon. Mary L. Cooper |
Vascepa® (icosapent ethyl capsules) |
8,293,728 |
Bristol-Myers Squibb Co. v. Aurobindo Pharma U.S.A., Inc., 14-3585 (D.N.J.) |
June 4, 2014 |
Hon. Mary L. Cooper |
Reyataz® (atazanavir sulfate capsules) |
6,087,383 |
AstraZeneca AB v. Apotex Corp., 14-61309 (S.D. Fla.) |
June 4, 2014 |
Hon. William P. Dimitrouleas |
Onglyza® (saxagliptin hydrochloride tablets) |
7,951,400 |
Teva Women's Health v. Lupin Ltd., 14-4055 (S.D.N.Y.) |
June 4, 2014 |
Hon. Lorna G. Schofield |
Quartette® (levonorgestrel / ethinyl estradiol tablets) |
8,415,332 |
Warner Chilcott Co., LLC v. Amneal Pharms. LLC, 14-0718 (D. Del.) |
June 6, 2014 |
Hon. Gregory M. Sleet |
Enablex® (darifenacin hydrobromide extended-release tablets) |
6,106,864 |
Warner Chilcott Co., LLC v. Lupin Atlantis Holdings S.A., 14-1827 (D. Md.) |
June 6, 2014 |
Hon. Roger W. Titus |
Minastrin® 24 Fe (ethinyl estradiol / norethindrone acetate tablets) |
6,667,050 |
Cipher Pharms. Inc. v. Actavis Labs. FL, Inc., 14-3653 (D.N.J.) |
June 6, 2014 |
Hon. Joseph E. Irenas |
Absorica® (isotretinoin capsules) |
7,435,427 |
Amarin Pharma, Inc. v. Teva Pharms. USA, Inc., 14-3251 (E.D. Pa.) |
June 6, 2014 |
Hon. Nitza I. Quinones Alejandro |
Vascepa® (icosapent ethyl capsules) |
8,293,728 |
Gilead Sciences, Inc. v. Mylan Inc., 14-0099 (N.D.W.V.) |
June 9, 2014 |
Hon. Irene M. Keeley |
Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) |
6,642,245 |
Vivus, Inc. v. Actavis Labs. FL, Inc., 14-3786 (D.N.J.) |
June 12, 2014 |
Hon. Faith S. Hochberg |
Qsymia® (phentermine / topiramate extended-release capsules) |
7,056,890 |
Alza Corp. v. Sandoz Inc., 14-0744 (D. Del.) |
June 13, 2014 |
Hon. Richard G. Andrews |
Concerta® (methylphenidate hydrochloride extended-release tablets) |
8,163,798 |
Vanda Pharms. Inc. v. Roxane Labs., Inc., 14-0757 (D. Del.) |
June 16, 2014 |
Hon. Gregory M. Sleet |
Fanapt® (iloperidone tablets) |
8,586,610 |
Alza Corp. v. Sandoz Inc., 14-3838 (D.N.J.) |
June 13, 2014 |
Hon. Joseph E. Irenas |
Concerta® (methylphenidate hydrochloride extended-release tablets) |
8,163,798 |
Novartis AG v. Glenmark Pharms., Ltd., 14-0771 (D. Del.) |
June 18, 2014 |
Hon. Leonard P. Stark |
Myfortic® (mycophenolate sodium delayed-release tablets) |
6,025,391 |
Merck Sharp & Dohme Corp. v. Fresenius Kabi USA, LLC, 14-3917 (D.N.J.) |
June 18, 2014 |
Hon. Peter G. Sheridan |
Emend® (fosaprepitant dimeglumine for injection) |
5,691,336 |
Amarin Pharma, Inc. v. Andrx Labs., LLC, 14-3924 (D.N.J.) |
June 18, 2014 |
Hon. Mary L. Cooper |
Vascepa® (icosapent ethyl capsules) |
8,293,728 |
Spectrum Pharms., Inc. v. Ben Venue Labs., Inc., 14-0980 (D. Nev.) |
June 18, 2014 |
Hon. Gloria M. Navarro |
Fusilev® (levoleucovorin calcium for injection) |
6,500,829 |
Cephalon, Inc. v. Actavis Labs. FL, Inc., 14-0776 (D. Del.) |
June 19, 2014 |
Hon. Sue L. Robinson |
Fentora® (fentanyl buccal tablets) |
6,200,604 |
Novartis Pharms. Corp. v. Mylan Inc., 14-0777 (D. Del.) |
June 19, 2014 |
Hon. Richard G. Andrews |
Exelon® (rivastigmine transdermal system or extended-release film) |
6,316,023 |
Allos Therapeutics, Inc. v. Teva Pharms. USA, Inc., 14-0778 (D. Del.) |
June 19, 2014 |
Hon. Richard G. Andrews |
Folotyn® (pralatrexate for injection) |
6,028,071 |
Pfizer Inc. v. CFT Pharms. LLC, 14-0781 (D. Del.) |
June 19, 2014 |
Hon. Sue L. Robinson |
Tygacil® (tigecycline injectable IV infusion) |
7,879,828 |
Cephalon, Inc. v. Actavis Labs. FL, Inc., 14-3936 (D.N.J.) |
June 19, 2014 |
Hon. Stanley R. Chesler |
Fentora® (fentanyl buccal tablets) |
6,200,604 |
Janssen Pharms., Inc. v. Roxane Labs., Inc., 14-3941 (D.N.J.) |
June 19, 2014 |
Hon. Claire C. Cecchi |
Nucynta® (tapentadol hydrochloride extended-release tablets) |
RE39,593 |
Teva Women's Health, Inc. v. Watson Labs., Inc., 14-4439 (S.D.N.Y.) |
June 19, 2014 |
Hon. John G. Koeltl |
Quartette® (levonorgestrel / ethinyl estradiol tablets) |
8,415,332 |
Otsuka Pharm. Co., Ltd. v. Par Pharm., Inc., 14-0789 (D. Del.) |
June 20, 2014 |
Hon. Richard G. Andrews |
Samsca® (tolvaptan tablets) |
5,753,677 |
Avanir Pharms., Inc. v. Ranbaxy Labs. Ltd., 14-0792 (D. Del.) |
June 20, 2014 |
Hon. Leonard P. Stark |
Nuedexta® (dextromethorphan hydrobromide / quinidine sulfate capsules) |
7,659,282 |
Senju Pharm. Co., Ltd. v. Metrics, Inc., 14-3962 (D.N.J.) |
June 20, 2014 |
Hon. Jerome B. Simandle |
Prolensa® (bromfenac ophthalmic solution) |
8,129,431 |
Otsuka Pharm. Co., Ltd. v. Intas Pharms. Ltd., 14-3996 (D.N.J.) |
June 20, 2014 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
8,017,615 |
Pfizer Inc. v. CFT Pharms. LLC, 14-0714 (E.D. Wis.) |
June 20, 2014 |
Hon. William E. Duffin |
Tygacil® (tigecycline injectable IV infusion) |
7,879,828 |
Novartis Pharms. Corp. v. Mylan Inc., 14-0106 (N.D.W.V.) |
June 20, 2014 |
Hon. Irene M. Keeley |
Exelon® (rivastigmine transdermal system or extended-release film) |
6,316,023 |
Biodelivery Sciences Int'l, Inc. v. RB Pharms. Ltd., IPR2014-00998 (PTAB) |
June 20, 2014 |
N/A |
Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) |
8,475,832 |
Amneal Pharms., LLC v. Jazz Pharms., Inc., CBM2014-00149 (PTAB) |
June 24, 2014 |
N/A |
Xyrem® (sodium oxybate oral solution) |
7,895,059 |
Novartis Pharms. Corp. v. Mylan Inc., 14-0820 (D. Del.) |
June 25, 2014 |
Hon. Richard G. Andrews |
Exjade® (deferasirox tablets for oral suspension) |
6,465,504 |
Shire LLC v. Ranbaxy Labs. Ltd., 14-0827 (D. Del.) |
June 25, 2014 |
Hon. Richard G. Andrews |
Intuniv® (guanfacine hydrochloride extended-release tablets) |
6,287,599 |
Orexo AB v. Actavis Elizabeth LLC, 14-0829 (D. Del.) |
June 26, 2014 |
Hon. Sue L. Robinson |
Zubsolv® (buprenorphine hydrochloride / naloxone hydrochloride dihydrate sublingual tablets) |
8,454,996 |
Eli Lilly and Co. v. Panacea Biotec, Ltd., 14-1064 (S.D. Ind.) |
June 26, 2014 |
Hon. Sarah Evans Barker |
Effient® (prasugrel hydrochloride tablets) |
8,404,703 |
Senju Pharm. Co., Ltd. v. Lupin, Ltd., 14-4149 (D.N.J.) |
June 26, 2014 |
Hon. Jerome B. Simandle |
Prolensa® (bromfenac ophthalmic solution) |
8,669,290 |
Novartis Pharms. Corp. v. Mylan Inc., 14-0111 (N.D.W.V.) |
June 26, 2014 |
Hon. Irene M. Keeley |
Exjade® (deferasirox tablets for oral suspension) |
6,465,504 |
Metrics, Inc. v. Senju Pharm. Co., Ltd., IPR2014-01041 (PTAB) |
June 26, 2014 |
N/A |
Prolensa® (bromfenac ophthalmic solution) |
8,129,431 |
Metrics, Inc. v. Senju Pharm. Co., Ltd., IPR2014-01043 (PTAB) |
June 26, 2014 |
N/A |
Prolensa® (bromfenac ophthalmic solution) |
8,669,290 |
Forest Labs., Inc. v. Aurobindo Pharma USA Inc., 14-0833 (D. Del.) |
June 27, 2014 |
Hon. Leonard P. Stark |
Namenda® (memantine hydrochloride tablets) |
5,061,703 |
UCB, Inc. v. Apotex Corp., 14-0834 (D. Del.) |
June 27, 2014 |
Hon. Leonard P. Stark |
Vimpat® (lacosamide oral solution) |
RE38,551 |
Par Pharm., Inc. v. Novartis Pharms. Corp., 14-0843 (D. Del.) |
June 27, 2014 |
Hon. Richard G. Andrews |
Exelon® (rivastigmine transdermal system or extended-release film) |
6,316,023 |
AstraZeneca AB v. Par Pharm., Inc., 14-0845 (D. Del.) |
June 30, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) |
7,951,400 |